Dapagliflozin - Wikipedia, the free encyclopedia
Dapagliflozin (rINN/USAN) is an experimental drug being studied by Bristol-Myers Squibb in partnership with AstraZeneca as a potential treatment for type 1 and 2 diabetes. Although dapagliflozin's method of action would...AZN,BMY Dapagliflozin Study Demonstrated Improved Glycemic Control In ...
TradingMarkets News for AZN,BMY - Dapagliflozin Study Demonstrated Improved Glycemic Control In Type 2 Diabetes Patients Treated With High Doses of Insulin and ...Dapagliflozin Study Demonstrated Improved Glycemic Control In Type 2 ...
PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--Results from a 12-week study demonstrated that the investigational drug dapagliflozin, a novel, selective,News: Dapagliflozin Study Demonstrated Improved Glycemic Control In ...
Results from a 12-week study demonstrated that the investigational drug dapagliflozin, a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, ...Type 2 Diabetes Patients Treated With Dapagliflozin Show Dose-Dependent ...
Dapagliflozin, a highly selective inhibitor of sodium glucose co-transporter 2 ... Patients were randomised to dapagliflozin (2.5, 5, 10, 20, or 50 mg/day) ...reportonbusiness.com: globeinvestor.com - Dapagliflozin Study ...
Overall adverse events across the dapagliflozin treatment arms were reported at ... Dapagliflozin is an investigational SGLT2 inhibitor currently in Phase 3 trials ...